SG11202100952QA - Method of preparing an antibody pharmaceutical formulation - Google Patents

Method of preparing an antibody pharmaceutical formulation

Info

Publication number
SG11202100952QA
SG11202100952QA SG11202100952QA SG11202100952QA SG11202100952QA SG 11202100952Q A SG11202100952Q A SG 11202100952QA SG 11202100952Q A SG11202100952Q A SG 11202100952QA SG 11202100952Q A SG11202100952Q A SG 11202100952QA SG 11202100952Q A SG11202100952Q A SG 11202100952QA
Authority
SG
Singapore
Prior art keywords
preparing
pharmaceutical formulation
antibody pharmaceutical
antibody
formulation
Prior art date
Application number
SG11202100952QA
Other languages
English (en)
Inventor
Ashutosh Sharma
Bryan Dransart
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of SG11202100952QA publication Critical patent/SG11202100952QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
SG11202100952QA 2018-08-10 2019-08-09 Method of preparing an antibody pharmaceutical formulation SG11202100952QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862717357P 2018-08-10 2018-08-10
PCT/US2019/045836 WO2020033788A1 (fr) 2018-08-10 2019-08-09 Procédé de préparation d'une formulation pharmaceutique d'anticorps

Publications (1)

Publication Number Publication Date
SG11202100952QA true SG11202100952QA (en) 2021-02-25

Family

ID=67734839

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202100952QA SG11202100952QA (en) 2018-08-10 2019-08-09 Method of preparing an antibody pharmaceutical formulation

Country Status (14)

Country Link
US (2) US20210308265A1 (fr)
EP (1) EP3833327A1 (fr)
JP (2) JP7425041B2 (fr)
KR (1) KR20210043607A (fr)
CN (1) CN112702991A (fr)
AU (1) AU2019316575A1 (fr)
BR (1) BR112021002506A2 (fr)
CA (1) CA3108693A1 (fr)
EA (1) EA202190482A1 (fr)
IL (1) IL280642A (fr)
MA (1) MA53272A (fr)
MX (1) MX2021001554A (fr)
SG (1) SG11202100952QA (fr)
WO (1) WO2020033788A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018115879A1 (fr) 2016-12-21 2018-06-28 Mereo Biopharma 3 Limited Utilisation d'anticorps anti-sclérostine dans le traitement de l'ostéogenèse imparfaite

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1391707A (en) 1918-08-15 1921-09-27 Viviano Philip Automatic change-speed transmission
ATE196606T1 (de) 1992-11-13 2000-10-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma
BRPI9915679B8 (pt) 1998-11-27 2021-05-25 Darwin Discovery Ltd composições e métodos para aumentar a mineralização óssea
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
RS20050934A (en) 2003-06-16 2008-04-04 Celltech R. & D. Inc., Antibodies specific for sclerostin and methods fo r increasing bone mineralization
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
BRPI0620316A2 (pt) * 2005-12-21 2011-11-08 Wyeth Corp formulações de proteìnas com viscosidades reduzida e seus usos
WO2008092894A1 (fr) 2007-02-02 2008-08-07 Novartis Ag Modulateurs de partenaires de liaison de la sclérostine pour traiter des troubles liés aux os
EP2131860B1 (fr) 2007-03-20 2013-12-18 Eli Lilly & Company Anticorps antisclérostine
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
PL2567709T3 (pl) 2007-11-02 2018-06-29 Novartis Ag Cząsteczki i sposoby modulowania białka związanego z receptorem dla lipoproteiny o niskiej gęstości 6 (LRP6)
WO2010100179A2 (fr) 2009-03-05 2010-09-10 Novartis Ag Système de gel autoformé pour administration de médicament à libération lente
AR075715A1 (es) 2009-03-05 2011-04-20 Novartis Ag Formulacion de anticuerpo liofilizado
WO2010115932A1 (fr) 2009-04-08 2010-10-14 Novartis Ag Combinaison pour traitement de perte osseuse
WO2010130830A2 (fr) 2009-05-15 2010-11-18 Ablynx N.V. Séquences d'acides aminés dirigées contre la sclérostine et polypeptides comprenant ces dernières pour le traitement de maladies et de pathologies des os
DK3195880T3 (da) * 2010-05-14 2020-03-02 Amgen Inc Højkoncentrerede anti-sclerostin-antistofformuleringer
WO2016109822A1 (fr) * 2014-12-31 2016-07-07 Novelmed Therapeutics, Inc. Formulation d'anticorps thérapeutiques aglycosylés
GB201604124D0 (en) * 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation

Also Published As

Publication number Publication date
EA202190482A1 (ru) 2021-05-25
WO2020033788A1 (fr) 2020-02-13
MX2021001554A (es) 2021-04-13
US20240342288A1 (en) 2024-10-17
CA3108693A1 (fr) 2020-02-13
MA53272A (fr) 2021-11-17
KR20210043607A (ko) 2021-04-21
JP2021534117A (ja) 2021-12-09
JP7425041B2 (ja) 2024-01-30
AU2019316575A1 (en) 2021-03-04
CN112702991A (zh) 2021-04-23
JP2024045250A (ja) 2024-04-02
BR112021002506A2 (pt) 2021-07-27
US20210308265A1 (en) 2021-10-07
IL280642A (en) 2021-03-25
EP3833327A1 (fr) 2021-06-16

Similar Documents

Publication Publication Date Title
IL279464A (en) Pharmaceutical formulation of odevixibat
HK1255006A1 (zh) 製備治療用蛋白質製劑的方法和由這種方法生產的抗體製劑
IL261989A (en) A pharmaceutical preparation of flavociclib and a method for its preparation
IL275639A (en) Formulation for RNA administration
EP3571467A4 (fr) Procédé d'imagerie de temps de vol épipolaire
GB201707484D0 (en) Method of preparing ph-dependent antibodies
ZA202007602B (en) Applicator and system for pharmaceutical preparation and method of use
EP3399996A4 (fr) Procédés d'administration d'hepcidine
IL281717A (en) Antibody formulation
EP3501477A4 (fr) Dispositif et procédé d'inspection de la préparation de médicaments
EP3432925A4 (fr) Administration d'un anticorps monoclonal anti-lgr5
IL282813A (en) Formulation of antibodies
SG11202009874QA (en) Antibody formulation
EP3733863A4 (fr) Procédé pour tester la sensibilité aux médicaments de cardiomyocytes
SG11202009315WA (en) Formulation and method of preparation
IL279622A (en) Pharmaceutical formulations of masked antibodies
EP3730620A4 (fr) Vaccin antigénique à immunisation croisée et son procédé de préparation
IL280642A (en) A method for preparing a pharmaceutical formulation for an antibody
EP3947448A4 (fr) Procédé d'administration d'un anticorps anti-ifn-alpha/-oméga
ZA201908090B (en) Pharmaceutical composition and method for preparing same
EP3247394A4 (fr) Formulation pharmaceutique comprenant des anticorps anti-egfr
IL266938A (en) Pharmaceutical preparation and method for its manufacture
IL281635A (en) A synthetic method for the preparation of Alkoxymethylene-Benzoyllactonitrile
GB201906748D0 (en) Method of formulation
HUP1800155A2 (en) Preparation method of fulvestrant